BNB Plus Corp. (BNBX) Stock Score, Valuation & Financial Research
BNB Plus Corp. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 24/100.
Quick answer for BNBX
BNB Plus Corp. currently has a Wall Street Score of 24/100. The stored market price is $0.16. Its financial score is 19/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What BNB Plus Corp. does
BNB Plus Corp., established in 1983 and based in Stony Brook, NY, is a biotechnology firm dedicated to pioneering and commercializing technologies for the synthesis and identification of both deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The company's operations are divided into three distinct business segments. Its Therapeutic DNA Production Services division specializes in the enzymatic manufacturing of synthetic DNA, used in the creation of nucleic acid-based treatments, and also develops and markets its proprietary RNA Polymerase (RNAP) for mRNA therapeutic production. The MDx Testing Services segment concentrates on developing clinical molecular diagnostic and genetic assessments, in addition to providing comprehensive clinical laboratory testing services. Lastly, the DNA Tagging and Security Products and Services segment leverages DNA detection techniques for securing ind
BNBX financial snapshot
- Wall Street Score:
- 24/100
- Current price:
- $0.16
- Market capitalization:
- $210K
- Revenue:
- $2.1M
- Net income:
- $-34.5M
- Free cash flow:
- $-12.8M
- Cash:
- $949K
- Total debt:
- $193K
- EPS:
- -39.93
- Financial score:
- 19/100
- Valuation score:
- 0/100
- Revenue score:
- 20/100
What stands out
- Reported year-over-year revenue growth is -0.0%.
- Free cash flow is $-12.8M, showing cash burn in the current stored period.
- The balance sheet shows $949K of cash versus $193K of total debt, leaving more cash than debt.
- The current research record carries a corporate distress warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 19/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-09.
How to research BNBX
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.